News

A web-based survey of Korean neurologists interested in narcolepsy presented their concerns with using the multiple sleep latency test, noting that it may lead to ambiguous results due to accompanying sleep disorders like sleep apnea.

A single dose of ubrogepant at its highest FDA-approved strength of 60 mg once daily had no statistically significant effect on atogepant pharmacokinetics.

Neurology News Network for the week ending February 4, 2023. [WATCH TIME: 4 minutes]

The clinical psychologist from Ayer Neuroscience Institute at Hartford Healthcare Headache Center shared some highlights from her recently published survey study on migraine treatment during pregnancy.

The list of women's contributions to the field of medicine is a long one, encompassing the hard work of hundreds of individuals. To highlight some of these pioneers, NeurologyLive® has compiled a timeline of 10 of the moments that matter in the history of women in medicine.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 3, 2023.

The chief training and education officer at the Parkinson’s Foundation discussed the importance of educating healthcare professionals on different specialists that play a role in Parkinson disease management. [WATCH TIME: 2 minutes]

In celebration of Women’s Physician Day, held February 3, 2022, take a look back at some of the latest conversations and news that were driven and delivered by women in neurology.

The director of the Montefiore Einstein Center for the Aging Brain provided insight on expanding the use of the 5-Cog tool, and whether it can be used for other conditions like HIV or COVID-19. [WATCH TIME: 3 minutes]

Treatment with deep brain stimulation resulted in improvements in mean motor scores, reductions levodopa equivalent dosage, and a decrease in neuropsychiatric features.

Majority of women’s healthcare providers reported in a survey feeling either somewhat or very comfortable with recommending or continuing acute treatments for pregnant patients with migraine.

Recruitment has begun for REGENXBIO's AFFINITY BEYOND clinical trial assessing the prevalence of AAV8 antibodies in male patients with Duchenne muscular dystrophy.

The pediatric neurologist at Nationwide Children's Hospital talked about current gaps and potential treatment approvals in epilepsy care for 2023. [WATCH TIME: 4 minutes]

An exergaming program that spanned 8 weeks showed positive effects for patients with multiple sclerosis both with and without restless legs syndrome.

The chief training and education officer at the Parkinson’s Foundation provided perspective on the vast types of medical professionals who can learn from the organization’s new education series. [WATCH TIME: 4 minutes]

With a PDUFA date of October 26, 2023, the FDA will review data from the phase 2b VISION-DMD study, in which vamorolone met its primary end point in change in TTSTAND velocity.

Branaplam, an mRNA splicing modifier, joins the many unsuccessful agents for Huntington disease as biopharma continues to be challenged with trial holds and failures.

Take a look at 5 of the most-anticipated clinical trial data readouts expected in 2023 that neurology health care professionals should keep their eyes on.

Donald Whiting, MD, chair of Allegheny Health Network’s Neurosciences Institute, provided insight on ADvance II, a multinational trial exploring the use of deep brain stimulation in patients with mild Alzheimer disease.

The psychologist and professor in the department of rehabilitation medicine at the University of Washington shared her perspective on the state of mental health care in multiple sclerosis. [WATCH TIME: 4 minutes]

The executive direct of Cure CMD discussed the state of care for patients with congenital muscular dystrophies, the need for new treatments, and the patience with gene therapies.

A cross-sectional and longitudinal comparative analysis suggests a subclinical neurodegenerative process may occur in MOG antibody disease based on a distinct pattern of brain atrophy.

Data from a cohort of more than 8000 participants suggest that older adults with less optimal sleep duration might benefit from moderate napping for their cognitive functions.

The pediatric neurologist at Nationwide Children's Hospital talked about the year-over-year changes in day-to-day clinical practice of patients with epilepsy. [WATCH TIME: 4 minutes]

In addition to showing a tolerable safety profile, EQU-001 resulted in reduced IL-17 and IL-1b plasma levels relative to baseline and limited the ability of peripheral mononuclear cells to secrete additional pro-inflammatory cytokines.

The chief training and education officer at the Parkinson’s Foundation provided perspective on a recently launched online program aimed at educating healthcare professionals. [WATCH TIME: 3 minutes]

After 12 weeks of treatment, almost twice as many patients on eptinezumab reported either “much improved” or “very much improved” than those on placebo, according to Patient Global Impression of Change.

Results from the CIRCLES cohort demonstrated a significant association in relapse patterns and disease phenotype for patients with NMOSD who change treatment.

Over a 2-year treatment period, no clear effects of dimethyl fumarate were identified on clinical or MRI outcomes in patients with progressive multiple sclerosis.